TREM2 and Alzheimer disease: INVOKE-2 was a randomized, double-blind, placebo-controlled, dose-ranging phase II clinical trial designed to evaluate the safety and efficacy of AL002, a TREM2-targeting monoclonal antibody, in patients with early-stage AD (Jackson et al., 2022).